•4-year data shows Vabymso delivers lasting DME results with fewer injections •Registration now open for first-ever Eyes On Practice Management•CooperVision expands US availability of Biofinity XR toric lenses•FDA grants TearSolutions' NK peptide therapy two FDA designations•Illinois Tech researchers report third implant of wireless visual prosthesis•4-year data shows Vabymso delivers lasting DME results with fewer injections •Registration now open for first-ever Eyes On Practice Management•CooperVision expands US availability of Biofinity XR toric lenses•FDA grants TearSolutions' NK peptide therapy two FDA designations•Illinois Tech researchers report third implant of wireless visual prosthesis
HEADLINES
FEATURED
Follows two failed FDA facility inspections; AVT06 will now undergo a 6-month review to become the sixth biosimilar of the name-brand VEGF inhibitor.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
